Status:
UNKNOWN
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
Lead Sponsor:
Stanford University
Conditions:
Liver Cirrhosis
Hemophilia
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to learn about the changes in coagulation factor VIII and IX levels in patients undergoing liver transplantation to help guide future management of coagulation ...
Detailed Description
Current guidelines for management of hemophilia B suggest replacement of factor IX to 100% prior to major abdominal surgery. However, in patients with concurrent liver cirrhosis where the liver does n...
Eligibility Criteria
Inclusion
- participants who have end stage liver disease who are listed for liver transplantation and have an accepted organ offer
- age \> 18+
- MELD \> 25
Exclusion
- undergoing multi-organ transplant
- tumor MELD exception points
- has hereditary coagulation disease
- currently on therapeutic blood thinner or anti-platelet medication (ie. aspirin, plavix, warfarin, heparin)
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06014320
Start Date
October 1 2023
End Date
October 1 2024
Last Update
August 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Hospital
Palo Alto, California, United States, 94305